(Q43439313)

English

Immunohistochemistry using the BRAF V600E mutation-specific monoclonal antibody VE1 is not a useful surrogate for genotyping in colorectal adenocarcinoma

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Immunohistochemistry using the BRAF V600E mutation-specific monoclonal antibody VE1 is not a useful surrogate for genotyping in colorectal adenocarcinoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

1 reference

based on heuristic

inferred from title

immunohistochemistry

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

monoclonal antibody

1 reference

based on heuristic

inferred from title

Jason L. Hornick

4

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

author name string

Cheryl A Adackapara

1

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Lynette M Sholl

2

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Justine A Barletta

3

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

publication date

13 June 2013

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

63

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

187-193

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12154

21 January 2018

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12154

21 January 2018

KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12154

21 January 2018

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12154

21 January 2018

Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers?

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12154

21 January 2018

Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers.

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12154

21 January 2018

Cetuximab for the treatment of colorectal cancer.

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12154

21 January 2018

Metastatic colon cancer, version 3.2013: featured updates to the NCCN Guidelines

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12154

21 January 2018

Molecular origins of cancer: Molecular basis of colorectal cancer

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12154

21 January 2018

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12154

21 January 2018

Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12154

21 January 2018

Monoclonal antibodies in gastrointestinal cancers.

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12154

21 January 2018

Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12154

21 January 2018

The clinical significance of serrated polyps.

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12154

21 January 2018

The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12154

21 January 2018

Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12154

21 January 2018

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12154

21 January 2018

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12154

21 January 2018

The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12154

21 January 2018

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12154

21 January 2018

Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12154

21 January 2018

BRAF V600E mutation analysis simplifies the testing algorithm for Lynch syndrome

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12154

21 January 2018

BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features.

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12154

21 January 2018

Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma.

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12154

21 January 2018

Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma.

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12154

21 January 2018

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12154

21 January 2018

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12154

21 January 2018

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12154

21 January 2018

Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12154

21 January 2018

Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients.

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12154

21 January 2018

Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing.

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12154

21 January 2018

Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12154

21 January 2018

Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR.

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12154

21 January 2018

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12154

21 January 2018

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12154

21 January 2018

Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) Diagnostics

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12154

21 January 2018

Identifiers

10.1111/HIS.12154

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43439313&oldid=1988869914"